Infant Bacterial Therapeutics AB is a high-risk pharmaceutical company based in Sweden. Specializing in developing drugs for premature babies, their main focus is on the ESG-friendly drug candidate IBP-9414. This drug aims to reduce the incidence of necrotizing enterocolitis (NEC) and improve gastrointestinal function using Lactobacillus reuteri, a bacterium naturally found in human breast milk. Additionally, their portfolio includes other potential lifesaving drugs such as IBP-1016, IBP-1118, and IBP-1122 for various medical conditions.